Deal Details

Upperton Receives Significant Investment from Inflexion

Healthcare

Upperton investment from Inflexion

Summary

Upperton Pharma Solutions (“Upperton”) has received a significant investment from Inflexion. Inflexion has invested alongside the founder and the management team who will continue to lead the business. As part of the investment, Inflexion will support Upperton in expanding its scale and capabilities commencing with the expansion of its manufacturing facility. The financial terms of the transaction were not disclosed.

Baird served as the exclusive financial advisor to Upperton Pharma Solutions on this transaction.

About

Upperton Pharma Solutions is a specialist CDMO providing formulation and dosage form development services to the biotechnology and pharmaceutical industries including virtual and small start-ups as well as global pharma companies. The company offers a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing. Furthermore, Upperton utilises an extensive range of formulation technologies, but in particular, it’s one of the world’s leaders on expertise and know-how in pharmaceutical spray drying; one of the most versatile and fast-growing technologies in the industry. Upperton was founded in 1999 and is based in Nottingham, the United Kingdom.

Inflexion is a UK-based private equity firm that seeks to make equity investments in a range of between GBP 10m and GBP 400m. Inflexion invests for minority and majority stakes in companies operating in the business services, financial services, infrastructure, healthcare, retail, consumer and technology sectors. Inflexion is currently investing out of Inflexion Enterprise Fund IV and Inflexion Supplemental Fund IV which were raised in May 2016, securing commitments of GBP 250m for each fund. Inflexion recently closed its latest funds Inflexion Buyout Fund V and Inflexion Partnership Capital Fund II. Inflexion Buyout Fund V and Partnership Capital Fund II were launched 4 months before they held final close on 21 May 2018, hitting hard caps of GBP 1.25bn and GBP 1bn, respectively.

Healthcare

Upperton investment from Inflexion